Ability of ultrasonography to detect cystic fibrosis in utero  by Scotet, V. et al.
S16 2. Screening/Diagnosis
58 Ability of ultrasonography to detect cystic ﬁbrosis in utero
V. Scotet1, I. Dugue´pe´roux1,2, M.P. Audre´zet1,2, M. Blayau3, C. Fe´rec1,2.
1Inserm U613, Brest, France; 2CHU, Lab. of molecular genetics, Brest, France;
3CHU, Lab. of molecular genetics, Rennes, France
Objective: Sonographic ﬁnding of fetal echogenic bowel (FEB) has been associated
with several pathologies such as chromosomal abnormalities, congenital infections
or cystic ﬁbrosis (CF). The aim of this study was to assess the ability of ultrasonog-
raphy to detect CF in utero.
Method: This study relied on the experience of Brittany (western France) where CF
is frequent. Such a study was possible in our region because a newborn screening
(NBS) program is set up since 1989 and because analysis of the CFTR gene
following a FEB diagnosis is also effective since the early 1990s. Combination
of the data from these two programs enabled to assess the proportion of CF fetuses
that were diagnosed by ultrasonography over the study period (period 1993–2007).
Results: Over the 15-year period, our NBS program screened 539,479 newborns and
identiﬁed 186 CF patients (incidence: 1/2900). A diagnosis of FEB had been made
in utero in 5 of them. Over the same time, 14 other pregnancies, in which a diagnosis
of FEB was made, were terminated because the molecular analysis revealed CF.
Consequently, among the 200 (186+14) CF cases over the study period, 19 (14+5;
9.5%) presented a FEB and were therefore diagnosed in utero by ultrasonography.
Conclusion: This study reveals that ultrasonography has led to identify close to
10% of the CF cases over the study period in our region. These ﬁndings are of
ﬁrst importance for clinicians who order testing for CF following a FEB diagnosis.
They highlight the efﬁciency of ultrasonography as a screening tool for CF in utero,
what contributes to modify the incidence of CF.
Supported by: Programme Hospitalier de Recherche Clinique.
59 First results of preimplantation genetic diagnosis of cystic ﬁbrosis
in Russia
P.A. Basanov1, P.A. Gogolevsky1, I.K. Gogolevsky2, M.A. Ivanov1,2,
N.J. Kashirskaya3, N.I. Kapranov3, M.A. Kurtser2. 1Clinic “Mother and
child”, Moscow, Russia; 2Center for family planning and reproduction, Moscow,
Russia; 3Cystic Fibrosis, Research centre for Medical Genetics RAMS, Moscow,
Russia.
Preimplantation genetic diagnosis (PGD) is an alternative for prenatal diagnosis
that makes it possible to perform the diagnosis of monogenic disorders at the
preimplantation embryo level. Cystic ﬁbrosis is one of the monogenic diseases for
which PGD can be performed.
In our study we report 8 cases of PGD for this particular disorder over a 3-year
period. 79 blastomeres underwent embryo biopsy in 8 IVF+ICSI cycles. After PGD
for CF mutations and PGS for common aneuploidies 19 of them were transfered
and 4 clinical pregnancies were achieved (pregnancy rate – 50%). 5 healthy babies
have been born already and there is one ongoing pregnancy. No misdiagnosis was
recorded.
We conclude that PGD is an effective alternative to prenatal diagnosis for couples
with an ethical or a religious objection to pregnancy termination and for infertile
patients carrying a genetic disorder. In our case pregnancy rate was 50%s, half of all
women that underwent their ﬁrst PGD cycle achieved a birth or ongoing pregnancy.
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For couples at risk of having children affected with Cystic Fibrosis (CF), preim-
plantation genetic diagnosis (PGD) is an alternative to prenatal diagnosis (PND)
thus avoiding selective termination of affected pregnancies. PGD is a procedure in
which one or two blastomeres from embryos obtained through in vitro fertilization
are analysed, after which embryos shown to be free of the disease under investigation
are transferred to the maternal uterus to initiate pregnancy. We report our experience
with PGD for CF.
From April 2002 to December 2008, 58 couples inquired about PGD for CF at
our center. Molecular analysis was performed for 34 families. Thirty PGD cycles
were initiated for 16 couples including couples with heterozygous partners carrier
of a severe CFTR gene mutation (n = 11), CF-affected male partners (n = 2), and
congenital bilateral absence of the vas deferens in males (n = 3). One to 3 genetically
unaffected embryos were selected for transfer in 19 cycles resulting in 7 clinical
pregnancies (36.8% per transfer): 1 was spontaneously aborted, 4 produced 5
unaffected live births, 1 twin pregnancy is still ongoing and 1 unaffected pregnancy
conﬁrmed by PND was selectively terminated because of an abnormal karyotype.
Over the years, we have constantly updated the technologies used and have now
evolved to a rapid and efﬁcient ﬂuorescent multiplex PCR protocol allowing the
simultaneous analysis of nine sequences either located within the CFTR gene
(F508del mutation, IVS1CA, IVS8CA, D7S677, IVS17bTA and IVS17bCA mark-
ers), or on each side of the gene (D7S486, D7S23 and AFM320vb5 polymorphisms).
This protocol is applicable to >95% of the couples requesting PGD for CF,
broadening the range of prenatal testing options for these families.
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Aim of study: to evaluate the possible inﬂuence of 21 trisomy on sweat test result
in cystic ﬁbrosis.
Material and Method: 5 month old female infant was admitted to hospital for
evaluation of particular phenotype. Clinical examination at admission revealed
hypotrophy, particular phenotype (epicanthic skin folds, eyelid slit, low-seat ears,
hypertelorism, epicanthus, a slightly open mouth with tongue protrusion, simian
crease, “sandal sign”), pallor, hypotonia, no pathological change in lungs at
auscultation; on cardiac auscultation: systolic murmur of III /VI degree, abdominal
muscular diastasis. The phenotype was assimilated to a Langdon-Down syndrome.
Results: The kariotype has conﬁrmed a structural chromosomal abnormality of
robertsonian translocation type between acrocentric chromosomes 21 and 22, and a
numerical chromosomal abnormality consistent with a total trisomy 21 type, the
cytopenic formula being: 46, XX, −22, +21, trob (21;22). The sweat test was
positive; NaCl 86mmol/l and 98mmol/l the second test. The genetic analysis
for cystic ﬁbrosis was negative for the 29 most common mutations for central-
eastern european area. Echocardiography revealed a common atrioventricular canal
complete form. An abdominal ultrasonography showed several images interpreted
as cholelithiasis.
Conclusion: The question is if there is an association between trisomy 21 and cystic
ﬁbrosis or another condition is the leading cause of false positive sweat test still
has to be answered.
